These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 12082849)

  • 21. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
    Zöller M; Matzku S
    Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccine therapy for cancer: fact or fiction?
    Odunsi K; Lele S; Savalgi R
    Surg Technol Int; 2004; 13():39-47. PubMed ID: 15744673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dendritic cells and their role in cancer immunotherapy.
    Jalili A
    Iran J Immunol; 2007 Sep; 4(3):127-44. PubMed ID: 17767012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antigen presentation by dendritic cells and their significance in antineoplastic immunotherapy.
    Bodey B; Siegel SE; Kaiser HE
    In Vivo; 2004; 18(1):81-100. PubMed ID: 15011756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy in head and neck cancer: current practice and future possibilities.
    Agada FO; Alhamarneh O; Stafford ND; Greenman J
    J Laryngol Otol; 2009 Jan; 123(1):19-28. PubMed ID: 18761763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spinning molecular immunology into successful immunotherapy.
    Pardoll DM
    Nat Rev Immunol; 2002 Apr; 2(4):227-38. PubMed ID: 12001994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How immunotherapy can enhance the response to other modalities and improve outcome and quality of life.
    Liu WM; Meyer B; Dalgleish AG
    J BUON; 2009 Sep; 14 Suppl 1():S103-9. PubMed ID: 19785052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progress in human tumour immunology and immunotherapy.
    Rosenberg SA
    Nature; 2001 May; 411(6835):380-4. PubMed ID: 11357146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic cancer vaccines.
    Acres B; Paul S; Haegel-Kronenberger H; Calmels B; Squiban P
    Curr Opin Mol Ther; 2004 Feb; 6(1):40-7. PubMed ID: 15011780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunotherapy for cancer--modern immunologic strategies in oncology].
    Halama N; Zoernig I; Jäger D
    Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined chemoimmunotherapy of solid tumours: improving vaccines?
    Nowak AK; Lake RA; Robinson BW
    Adv Drug Deliv Rev; 2006 Oct; 58(8):975-90. PubMed ID: 17005292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Current status and future perspective of cancer vaccine development].
    Sasada T; Itoh K
    Gan To Kagaku Ryoho; 2011 Apr; 38(4):503-8. PubMed ID: 21498975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses.
    Durrant LG; Pudney V; Spendlove I; Metheringham RL
    Expert Opin Biol Ther; 2010 May; 10(5):735-48. PubMed ID: 20384522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.
    Noy R; Eppel M; Haus-Cohen M; Klechevsky E; Mekler O; Michaeli Y; Denkberg G; Reiter Y
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):523-36. PubMed ID: 16250828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal control in a model of dendritic cell transfection cancer immunotherapy.
    Castiglione F; Piccoli B
    Bull Math Biol; 2006 Feb; 68(2):255-74. PubMed ID: 16794930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapeutics in development for prostate cancer.
    Harzstark AL; Small EJ
    Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune monitoring of cancer patients undergoing experimental immunotherapy.
    Shankar G; Salgaller ML
    Curr Opin Mol Ther; 2000 Feb; 2(1):66-73. PubMed ID: 11249653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumour immunotherapy: the adjuvant treatment of the 21st century?
    Bremers AJ; Kuppen PJ; Parmiani G
    Eur J Surg Oncol; 2000 Jun; 26(4):418-24. PubMed ID: 10873365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Active immunization against cancer cells: impediments and advances.
    Velders MP; Schreiber H; Kast WM
    Semin Oncol; 1998 Dec; 25(6):697-706. PubMed ID: 9865683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.